{"schema_version":"secwatch.filing_event.v1","accession":"0001200375-22-000037","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.854322+00:00","generated_at":"2026-06-22T08:07:44.249433+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Codexis Q3 2022 revenue $34.5M, net loss $10.0M; reaffirms FY2022 guidance","bullets":["Total Q3 revenue $34.5M, down 6% YoY from $36.8M; net loss $10.0M ($0.15/share) vs net income $2.2M in Q3 2021.","Product revenue $28.0M, down 2%; excluding COVID drug (PAXLOVID) sales, product revenue up 53% to $15.1M.","Reiterated FY2022 guidance: total revenue $135-141M, product revenue $112-118M (incl ~$75M from Pfizer).","New CEO Dr. Stephen Dilly, COO Kevin Norrett, GC Margaret Fitzgerald appointed; Rahul Singhvi added to Board.","Cash and equivalents $108.7M; expects cash to fund operations through at least end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001200375-22-000037","json":"https://secwatch.observer/filing/0001200375-22-000037.json","markdown":"https://secwatch.observer/filing/0001200375-22-000037.md","text":"https://secwatch.observer/filing/0001200375-22-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000120037522000037/0001200375-22-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000120037522000037/cdxs-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:07:44.249433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2325783ceec351cf0af28f9dffb1a51704ec0c9","claim":"CODEXIS, INC. reported third quarter ended September 30, 2022 results: revenue $34.5 million, net income $(10.0) million, or $0.15 per share, EPS $0.15 per share. Guidance reaffirmed.","evidence_excerpt":"Total revenues for the third quarter 2022 were $34.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037522000037/0001200375-22-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$34.5 million"},{"label":"Net income","value":"$(10.0) million, or $0.15 per share"},{"label":"EPS","value":"$0.15 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}